Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30996206 | 0.87 | CA2 (0.44) | GABRA1GABRB2CA2ALDH1A1TSHR | |
| SCHEMBL4748714 | 0.82 | GABRA1 (0.40) | GABRA1GABRB2CA2ALDH1A1TSHR | |
| SCHEMBL16990195 | 0.80 | CA2 (0.39) | GABRA1GABRB2CA2ALDH1A1TSHR | |
| SCHEMBL3135046 | 0.76 | KIF11 (0.33) | CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL27699133 | 0.75 | CA2 (0.38) | GABRA1GABRB2CA2ALDH1A1TSHR | |
| SCHEMBL1927917 | 0.75 | GABRA1 (0.58) | GABRA1GABRB2CA2ALDH1A1KDM4E | |
| SCHEMBL22471766 | 0.72 | BCL2L1 (0.32) | — | |
| SCHEMBL14877302 | 0.72 | GABRA1 (0.60) | GABRA1GABRB2CA2ALDH1A1KDM4E | |
| SCHEMBL3749865 | 0.72 | CA2 (0.46) | GABRA1GABRB2CA2ALDH1A1KDM4E | |
| SCHEMBL22829805 | 0.72 | GABRA1 (0.45) | GABRA1GABRB2CA2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799941-B2 | Process for producing optically active β-hydroxy-α-aminocarboxylic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20060167300-A1 | Process for producing optically active ss-hydroxy alpha aminocarboxylic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1650185-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE BETA-HYDROXY- ALPHA-AMINOCARBOXYLIC ACID DERIVATIVES | Nissan Chemical Industries, Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167300-A1 | Process for producing optically active ss-hydroxy alpha aminocarboxylic acid derivative | ALDH7A1, HCAR1, ALAD | GABRA1 703/4885GABRB2 1448/4885CA2 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.